Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Accumulated Depreciation & Amortization: 2015-2020

Historic Accumulated Depreciation & Amortization for Outlook Therapeutics (OTLK) over the last 6 years, with Sep 2020 value amounting to $40,906.

  • Outlook Therapeutics' Accumulated Depreciation & Amortization fell 95.40% to $40,906 in Q3 2020 from the same period last year, while for Sep 2020 it was $219,416, marking a year-over-year decrease of 93.47%. This contributed to the annual value of $219,416 for FY2020, which is 93.47% down from last year.
  • Outlook Therapeutics' Accumulated Depreciation & Amortization amounted to $40,906 in Q3 2020, which was down 19.73% from $50,959 recorded in Q2 2020.
  • Outlook Therapeutics' 5-year Accumulated Depreciation & Amortization high stood at $888,868 for Q3 2019, and its period low was $40,906 during Q3 2020.
  • In the last 3 years, Outlook Therapeutics' Accumulated Depreciation & Amortization had a median value of $816,541 in 2019 and averaged $539,456.
  • Per our database at Business Quant, Outlook Therapeutics' Accumulated Depreciation & Amortization spiked by 169.32% in 2016 and then plummeted by 95.40% in 2020.
  • Quarterly analysis of 5 years shows Outlook Therapeutics' Accumulated Depreciation & Amortization stood at $669,780 in 2016, then increased by 1.02% to $676,624 in 2017, then climbed by 21.64% to $823,077 in 2018, then plummeted by 92.25% to $63,776 in 2019, then plummeted by 95.40% to $40,906 in 2020.
  • Its last three reported values are $40,906 in Q3 2020, $50,959 for Q2 2020, and $63,775 during Q1 2020.